Web19 jan. 2024 · Ionis Pharmaceuticals (IONS) reported that its partner Biogen (BIIB) presented new Phase 1b clinical data showing that IONIS-MAPTRx reduced soluble tau protein in cerebrospinal fluid in a dose-dependent and sustained manner in patients with early-stage Alzheimer's disease. Web7 mrt. 2024 · Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) …
IONIS PHARMACEUTICALS, INC. : Stock Market News and …
Web11 feb. 2024 · CARLSBAD, Calif., Feb. 11, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that the European Medicines Agency (EMA) has granted orphan drug designation to ION373 for the treatment of people with Alexander disease, a severe, progressive and debilitating … WebIONS Complete Ionis Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. graphic identiy chart
Ionis reports positive topline 66-week results of eplontersen Phase …
Web8 dec. 2024 · Ionis Pharmaceuticals Show advanced filters news Oligonucleotide synthesis market to reach $16.7 billion by 2027 9 December 2024 By Catherine Eckford (European Pharmaceutical Review) Ongoing clinical trials for oligonucleotide-based therapies will propel the oligonucleotide synthesis market to reach $16.7 billion by 2027, … Web29 mrt. 2024 · Mar 27, 2024 Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN Mar 22, 2024 Ionis announced FDA advisory committee voted unanimously for a potential accelerated approval of … Web27 mrt. 2024 · For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three... chiropodist hedge end